Nonmetastatic Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 6, 2021
August 6, 2021
c32357fc-c9d0-4e62-95cb-8b3f815da638
Related Documents
Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry
Guidance DocumentAugust 29, 2019Center for Drug Evaluation and Research
General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry
Guidance DocumentJuly 27, 2022Center for Drug Evaluation and Research
Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials
Guidance DocumentMarch 13, 2019Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox